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Abstract 
Background: The protective role of high HDL cholesterol levels against cardiovascular diseases has been recently 
questioned. Limited data are available on this specific topic in patients with type 2 diabetes mellitus (T2DM). We 
aimed to evaluate the association of HDL cholesterol concentrations with all-cause and cause-specific mortality in a 
historical cohort of T2DM patients with 14 years of follow-up.
Methods: This is a retrospective population-based cohort study involving 2113 T2DM patients attending the Dia-
betic Clinic of Asti. Survival analyses were performed to assess hazard ratios for overall and specific-cause mortality by 
HDL cholesterol tertiles, using the middle HDL cholesterol tertile as a reference.
Results: The mean age was 66 ± 11 years; 51.4% of patients had low HDL-cholesterol levels. After a 14-year follow-up, 
973/2112 patients had died (46.1%). The HDL cholesterol tertile cut-off points were 37.5 and 47.5 mg/dL (males) and 
41.5 and 52.0 mg/dL (females). No associations between lower and upper HDL cholesterol tertiles respectively and 
all-cause (HR = 1.12; 95% CI 0.96–1.32; HR = 1.11; 0.95–1.30), cardiovascular (HR = 0.97; 0.77–1.23; HR = 0.94; 0.75–1.18) 
or cancer (HR = 0.92; 0.67–1.25; HR = 0.89; 0.66–1.21) mortality were found. A significantly increased risk for infectious 
disease death was found both in the lower (HR = 2.62; 1.44–4.74) and the upper HDL-cholesterol tertiles (HR = 2.05; 
1.09–3.85) when compared to the reference. Individuals in the upper tertile showed an increased risk for mortality due 
to diabetes-related causes (HR = 1.87; 1.10–3.15).
Conclusions: Our results corroborate the hypothesis that HDL cholesterol levels are nonprotective in T2DM patients. 
The U-shaped association between HDL-cholesterol levels and mortality associated with infectious diseases should be 
verified by further studies.
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Background
The level of HDL cholesterol is influenced by common 
and rare genetic variants, elevated blood triglyceride 
levels, obesity, smoking, sedentarism and alcohol con-
sumption [1]. Recent findings have shown that HDL 
function can be negatively affected by aging, systemic 
diseases and/or inflammatory statuses without changes 
in HDL cholesterol concentrations [2–4]. This compli-
cates the interpretation of the observed associations 
Page 2 of 9Fanni et al. J Transl Med          (2020) 18:189 
between HDL cholesterol levels and cardiovascular (CV) 
risk [5].
Evidence from epidemiological studies has raised doubt 
about the protective role of high HDL cholesterol levels 
against CV disease (CVD) risk; intriguingly, U-shaped 
associations between HDL cholesterol concentrations 
and CVD risk and mortality have been reported [6–11]. 
The conformational and functional properties of HDL 
particles may be altered in individuals with extremely 
high HDL cholesterol and HDL functionality may be 
compromised such that those particles no longer func-
tion but rather cause harm [1].
Patients with type 2 diabetes mellitus (T2DM) are char-
acterized by an atherogenic lipidic profile with reduced 
HDL cholesterol concentrations, even though the precise 
underlying mechanisms have not been completely under-
stood [12, 13]. HDL particles are known to be highly 
heterogeneous in structure and content. The chronic 
inflammatory state and non-enzymatic apolipoprotein 
glycation that occur in T2DM contribute to altering the 
relative composition of HDL and impairing HDL-associ-
ated anti-inflammatory and anti-atherogenic properties 
[2, 14–17], thus hampering the protective effect of HDL 
on vessels.
To the best of our knowledge, only one study has been 
carried out to analyze the associations among HDL cho-
lesterol, CV risk and mortality in patients affected by 
T2DM, showing increased all-cause and CV mortality in 
patients in the two extreme HDL cholesterol quartiles in 
the presence of LDL cholesterol < 77 mg/dL. This associa-
tion was not found in patients with higher LDL choles-
terol levels [8].
Despite the well-known lower HDL cholesterol levels 
in fasting or postprandial states that characterize about 
approximately half of all individuals with T2DM [18, 
19], there are no specific HDL cholesterol cut-off val-
ues for these patients. Furthermore, no specific goals 
for HDL cholesterol levels have been defined, even in 
the most updated guidelines for the general population 
[20]. Finally, the heterogeneity of cut-off values and refer-
ence range limits among studies on this topic impaired 
adequate comparison and interpretation of existing 
literature.
The aims of this retrospective population-based study 
were to evaluate the association of HDL cholesterol con-
centrations with overall and cause-specific mortality in a 
historical cohort of T2DM patients after a 14-year follow-
up in a real-world setting. The advantages of this cohort 
were the low number of patients treated with statins/
fibrates and the unavailability of the new hypoglycemic 
drugs that greatly impact studied outcomes, thus reduc-
ing the likelihood of those confounding factors affecting 
the results.
Materials and Methods
Study design and participants
All 2113 patients with T2DM attending the Diabetic Clinic 
of Asti, in a province in Northern Italy, were evaluated in 
1996–1997, as previously reported [21, 22]. They repre-
sented 1.6% of the reference population (134 646 subjects). 
Since the prevalence of known T2DM was 2% in Northern 
Italy in that period [23], our cohort included approximately 
80% of the patients with known diabetes in the study area.
All the procedures were conducted in accordance 
with the Declaration of Helsinki; informed consent was 
obtained from all the patients at baseline, and the study was 
approved by the Ethics Committee of the Hospital of Asti.
Baseline data of all the patients attending our clinic in 
1996–1997 were obtained from the clinical records in our 
Diabetic Clinic from those years. At the Diabetic Clinic, 
all patients were examined every 4 months, the glycated 
hemoglobin (HbA1c) and arterial blood pressure levels 
were measured at each visit, and the patients received 
annual plasma lipid measurements and screenings for 
chronic complications. All laboratory measurements 
were centralized. Height and weight were measured by 
a trained nurse with the patient wearing light clothing 
and no shoes. The arterial blood pressure was measured 
by the same nurse in the morning after an overnight fast 
using a mercury sphygmomanometer with an appropri-
ate cuff size, after a 5-min rest in a seated position with 
the arm being supported at heart level.
The values reported were the averages of the last three 
measurements reported in the clinical records.
Retinopathy was diagnosed via an ophthalmoscopic 
examination and/or retinal photography. A fundoscopy 
was performed through dilated pupils by an ophthal-
mologist who was experienced in diabetic retinopathy. 
In the group with retinopathy (any degree), a retinal 
photograph was taken, in accordance with the European 
protocol for diabetic retinopathy [23]. Nephropathy was 
established according to an albumin excretion rate of 
more than 20  µg/min in at least two out of three urine 
collections within 6  months (immunoturbidimetric 
method), gross proteinuria or elevated serum creatinine 
[24]. Distal symmetric polyneuropathy was diagnosed 
by the presence of neuropathic symptoms, an abnormal 
vibration perception threshold, the absence of ankle or 
knee reflexes and/or an abnormal electromyographic 
test. Autonomic neuropathy was diagnosed by a loss of 
heart rate variability or postural hypotension. A CV dis-
ease (CVD) diagnosis was based on documented events 
that were recorded by a physician (angina, myocardial 
infarction, a coronary artery bypass graft or other inva-
sive procedures to treat coronary artery disease, transient 
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ischemic attacks, strokes, gangrene, amputation, vascular 
surgery, intermittent claudication, absent foot pulses and 
abnormal brachial and posterior tibial blood pressures, as 
determined by Doppler techniques).
Information on the vital status of each patient and the 
causes of death of those who had died were collected 
from June to December 2010 from the demographic 
files in the town of residence or death. The underlying 
causes of death were determined from death certificates 
and coded according to the International Classification 
of Diseases, Ninth Revision (ICD-9) [25]. The vital sta-
tus and cause of death were ascertained for 99.9% of the 
cohort (2112/2113). Among the causes of death, CVD 
(ICD 410–414, 430–438, 440), cancer (140–239), diabetes 
(250), and infectious diseases (001-139) were considered.
Statistical methods
Patients were divided into tertiles according to HDL cho-
lesterol levels and sex.
A two-sided log-rank test with an overall sample size 
of 2100 subjects (699 in the second HDL tertile and 1414 
in the lower and upper HDL tertiles) achieves 80% power 
at a 0.05 significance level to detect a hazard ratio of 1.20 
when the reference group hazard ratio is 1.00. ANOVA, 
the Kruskal–Wallis test or the Chi square test was used as 
appropriate to compare the clinical characteristics of the 
patients among tertile groups. The Kaplan–Meier curves 
were assessed by the log rank test and plotted by the HDL 
tertiles. The Cox regression model was used for survival 
analysis (all-cause mortality). Fine and Gray’s hazard 
model was used for the competing risk analyses (cause-
specific mortality). The estimates were adjusted for sex, 
age, age at diabetes diagnosis, alcohol intake, smoking hab-
its, values of HbA1c, non-HDL cholesterol (calculated as 
the difference between total cholesterol and HDL choles-
terol), creatinine clearance, presence of CVDs at baseline, 
and treatment with sulfonylureas, insulin and hypolipemic 
drugs. The middle HDL cholesterol tertile was used as a 
reference.
Results
The HDL cholesterol cut-off points of the tertiles were 
37.5  mg/dL and 47.5  mg/dL for males and 41.5  mg/
dL and 52.0  mg/dL for females, respectively (Table  1). 
Patients in the lower HDL cholesterol tertile were 
younger, more frequently insulin-treated (31.4%), and 
showed increased values of BMI, triglycerides, uric acid, 
C-peptide, prevalence of metabolic syndrome and lower 
total cholesterol, statin (3.0%) and metformin (69.0%) 
treatment rates.
During a 14-year follow-up, 973 of 2112 patients died 
(46.1%). The survival analysis showed non-linear associa-
tions for all outcomes (Table 2). Patients belonging to the 
lower and to the upper HDL cholesterol tertiles did not 
show significant differences in all-cause, CV or cancer 
mortality with respect to the reference category, even if a 
slight increase in all-cause mortality was evident in those 
two tertiles. Mortality associated with infectious dis-
eases was significantly higher in both these groups when 
compared to the middle tertile (Table 2), while mortality 
related to diabetes was significantly associated only with 
the upper HDL cholesterol tertile. No significant associa-
tion was found between HDL cholesterol and mortality 
for causes other than those indicated above. The Kaplan–
Meier curves for overall, CVD and cancer survival are 
shown in Fig.1.
After the exclusion of the 646 patients affected by CVD 
at baseline, the results of the survival analysis did not 
change significantly (data not shown), with the excep-
tion of a significantly higher risk for all-cause mortality 
(HR = 1.28; 95% CI 1.04–1.59) and diabetes mortality 
(HR = 2.53; 1.14–5.61) in patients in the lower HDL cho-
lesterol tertile. Furthermore, the data did not change 
after excluding the 50 patients with known chronic liver 
diseases from the survival analyses.
Discussion
In this cohort of T2DM patients, we found a U-shaped 
relationship between HDL cholesterol levels and mortal-
ity from infectious diseases and an increased diabetes-
related mortality rate in individuals in the upper HDL 
cholesterol tertile, but no significant associations were 
found between HDL cholesterol levels and all-cause, 
CVD and cancer mortality.
HDL cholesterol and metabolic pattern
As expected, in our T2DM cohort, higher HDL cho-
lesterol values were significantly associated with lower 
triglycerides and higher total cholesterol serum levels. 
These data reflect the characteristic pattern of diabetic 
dyslipidemia [12, 26]. Furthermore, the prevalence of 
metabolic syndrome in the upper HDL cholesterol tertile 
was lower, consistent with the lower BMI. A likely lower 
level of insulin resistance of those individuals could be 
inferred as a consequence of their lower C-peptide levels.
The main function of HDL particles is reverse choles-
terol transport from peripheral tissues to the liver. HDL 
particles show antioxidant, anti-inflammatory and anti-
thrombotic properties [27–29]. Low HDL cholesterol 
together with higher triglyceride blood concentrations 
characterize so-called atherogenic dyslipidemia in T2DM 
patients. Indeed, both hyperglycemia and insulin resist-
ance have been shown to impact HDL particles in differ-
ent ways: by altering the HDL subspecies proportion in 
favor of the small-dense  HDL3 with respect to the large 
 HDL2; by altering the HDL proteome; by modifying the 
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enzymatic activity of HDL-associated proteins, such as 
lecithin-cholesterol acyltransferase (LCAT) and paraoxo-
nase-1 (PON-1); by increasing HDL hepatic catabolism 
through an enhanced activity of hepatic lipase; and by 
reducing their anti-inflammatory activity mediated by 
apolipoprotein A1 (ApoA-I) [13–17]. All these alterations 
contribute to hindering the anti-inflammatory and anti-
atherogenic activity of HDL in T2DM patients.
All‑cause and specific‑cause mortality
We would have expected lower overall and cause-specific 
CV mortality in patients in the upper HDL cholesterol 
tertile due to their overall better metabolic pattern. In 
contrast, all-cause and CV-related mortalities were not 
significantly affected by HDL cholesterol levels in our 
whole cohort. However, patients without CVD at baseline 
in the lower HDL tertile showed a slightly increased risk 
for all-cause mortality, thus confirming the well-known 
negative role of low HDL cholesterol serum concentra-
tion in individuals in primary prevention [30]. The effec-
tiveness of HDL cholesterol quantity as a trustworthy 
marker for CV protection has been recently questioned 
[2]. Mutant ApoA-I Milano is a paradigmatic example of 
this incongruence: carriers of this mutation display very 
low levels of HDL cholesterol and are markedly protected 
from CVD [31]. Attempts to increase HDL cholesterol 
levels via cholesteryl ester transfer protein (CETP) inhib-
itors such as torcetrapib failed to confer atheroprotection 
[32, 33].
A 2-to-threefold increased risk for all-cause mortality 
has been reported in Danish individuals with very high 
HDL cholesterol levels (> 97 mg/dL for males, > 116 mg/
dL for females) when compared to the group with the 
lowest risk (i.e. males with HDL cholesterol values of 
58–76  mg/dL and females with HDL cholesterol val-
ues of 77–96  mg/dL) [7]. A slightly higher, though 
Table 1 Characteristics of the T2DM patients by HDL cholesterol tertiles
*Kruskal–Wallis test
Lower tertile
< 41.5 mg/dL F
< 37.5 mg/dL M
Middle tertile
41.5 ≤ and < 52 mg/dL F
37.5 ≤ and < 47.5 mg/dL M
Higher tertile
≥52 mg/dL F
≥47.5 mg/dL M
P
Number 700 699 714
Males (%) 45.3 45.2 43.7 0.79
Age (years) 64.6 ± 11.8 65.8 ± 10.4 67.6 ± 10.1 < 0.001
Age of DM diagnosis 55.8 ± 12.5 55.4 ± 10.7 56.1 ± 10.7 0.57
Smoking (%) 16.7 15.6 12.9 0.12
Treated with insulin (%) 31.4 23.9 27.0 0.007
Treated with sulfonylureas (%) 64.4 69.4 67.9 0.13
Treated with metformin (%) 69.0 65.8 72.3 0.032
Treated with statins (%) 3.0 6.9 9.0 <0.001
Treated with fibrates (%) 8.4 4.0 2.1 < 0.001
Treated with hypotensive drugs (%) 52.0 53.4 51.1 0.70
Treated with ACE-inhibitors 33.6 33.6 29.7 0.19
Treated with acetylsalicylic acid (%) 33.4 32.9 29.0 0.15
BMI (kg/m2) 29.4 ± 5.5 29.2 ± 5.1 27.6 ± 4.7 < 0.001
Systolic blood pressure (mmHg) 143.2 ± 11.4 143.6 ± 11.3 144.3 ± 11.1 0.21
Diastolic blood pressure (mmHg) 83.4 ± 4.5 83.0 ± 4.2 83.2 ± 4.5 0.23
HbA1c (%) 6.7 ± 1.5 6.6 ± 1.2 6.5 ± 1.2 0.12
C-peptide (ng/mL) * 2.3 ± 1.4 2.0 ± 1.2 1.8 ± 1.1 < 0.001
Total cholesterol (mg/dL) 198.2 ± 47.0 209.1 ± 39.5 213.4 ± 40.0 < 0.001
Triglycerides (mg/dL) * 177.6 ± 118.2 139.7 ± 75.2 106.3 ± 56.8 < 0.001
Uric acid (mg/dL) 5.5 ± 1.7 5.3 ± 1.5 5.0 ± 1.4 < 0.001
Creatinine clearance (mL/min) 107.1 ± 48.3 106.9 ± 42.6 105.8 ± 40.0 0.83
Retinopathy (%) 20.9 20.9 21.9 0.87
Nephropathy (%) 22.7 22.0 21.4 0.84
Neuropathy (%) 9.6 9.3 8.5 0.78
Coronary artery diseases (%) 21.3 20.0 16.5 0.06
Peripheral vascular diseases (%) 18.1 17.0 16.1 0.59
Metabolic syndrome (%) 64.1 45.6 33.5 < 0.001
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not statistically significant, risk for all-cause and can-
cer mortality was found in south Korean adults with 
HDL cholesterol levels > 85  mg/dL [6]. Increased all-
cause (HR = 1.56; 95% CI 1.08–2.26), CV (HR = 1.62; 
0.86–3.05) and non-CV deaths (HR = 1.45; 0.93–2.27) 
were found in US elderly individuals with HDL choles-
terol levels > 90  mg/dL [9]. In an American prospective 
study, high HDL cholesterol levels (80–100 mg/dL) were 
found to be associated with an increased risk for overall 
(RR = 1.25; 1.09–1.49), coronary heart disease (RR = 1.09; 
1.02–1.32) and stroke (RR = 1.11; 1.02–1.32) mortalities 
[10].
The high heterogeneity of HDL subspecies accounts 
for their different capabilities in reverse cholesterol 
transport and in atheroprotection [34, 35]. In the 
presence of chronic subclinical inflammation, such 
as in coronary artery disease, impaired HDL vessel-
protecting functions have been reported even without 
alteration in HDL cholesterol blood concentrations, 
which may remain in the normal range [2, 4, 5, 7]. 
Similarly, in T2DM patients, characterized by chronic 
subclinical inflammation status and by the aforemen-
tioned atherogenic dyslipidemia, reaching normal or 
even high HDL cholesterol levels might not be effec-
tive in conferring atheroprotection [4, 13]. Only one 
study specifically addressed the relationships between 
HDL cholesterol levels and major outcomes in T2DM 
patients, showing a direct association between HDL 
cholesterol and all-cause mortality (HR = 1.14; 1.07–
1.22 per 4 mg/dL HDL cholesterol increase), CV mor-
tality (HR = 1.12; 1.03–1.22) and CV fatal and nonfatal 
events (HR = 1.10; 1.02–1.18) in the presence of LDL 
cholesterol levels < 77  mg/dL. In contrast, in patients 
with LDL cholesterol levels ranging between 77 and 
97  mg/dL, higher HDL cholesterol was associated 
with a lower CV risk (HR = 0.85; 0.75–0.95 per 4  mg/
dL HDL cholesterol increase) [8]. These counterintui-
tive relationships have been explained by the authors as 
possible confounding effects of statin treatment, which 
is responsible for both the reduction in LDL choles-
terol serum concentration and the inhibition of hepatic 
lipase, a key enzyme in HDL catabolism. A reduction 
in lipase activity is indeed associated with an increase 
in HDL cholesterol levels and contemporarily with an 
increased risk for CV events.
As previously reported, HDL function is impaired in 
T2DM patients, independent of HDL cholesterol serum 
levels [15, 16]. In our cohort, patients in the upper HDL 
cholesterol tertile were older than those in the other ter-
tiles. This could have strongly impacted the evaluated 
outcomes. However, our results did not change after 
adjustment for age. If these results are confirmed by 
Table 2 Adjusted hazard ratios for all cause and cause-specific mortality in type 2 diabetic patients by HDL cholesterol 
tertiles
a Hazard ratios adjusted for gender, age, age at diabetes diagnosis, alcohol intake, smoking habits, values of non-HDL cholesterol, HbA1c and creatinine clearance, 
presence of CV diseases at baseline, treatment with sulfonylureas, insulin and hypolipemic drugs
b Fine and Gray’s hazard model for the competing risk analyses
Mortality Lower tertile p Middle tertile Upper tertile p
All causes
Number of deaths 330 297 346
HRa (95% CI) 1.12 (0.96–1.32) 0.15 1 1.11 (0.95–1.30) 0.21
Cardiovascular diseases
Number of deaths 148 152 158
HRb (95% CI) 0.97 (0.77–1.23) 0.80 1 0.94 (0.75–1.18) 0.60
Cancer
Number of deaths 85 87 84
HRb (95% CI) 0.92 (0.67–1.25) 0.57 1 0.89 (0.66–1.21) 0.47
Infectious diseases
Number of deaths 37 15 33
HRb (95% CI) 2.62 (1.44–4.74) 0.002 1 2.05 (1.09–3.85) 0.03
Diabetes
Number of deaths 34 21 43
HRb (95% CI) 1.64 (0.94–2.87) 0.08 1 1.87 (1.10–3.15) 0.02
Other causes
Number of deaths 26 22 28
HRb (95% CI) 1.16 (0.67–2.03) 0.60 1 1.05 (0.59–1.86) 0.87
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Fig. 1 Kaplan-Meyer curves relative to overall, CVD and cancer survival by HDL tertiles. In blue, the first (lower) tertile, in dotted red, the second 
(middle) tertile, in dotted black, the third (higher) tertile
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larger prospective studies, it could be hypothesized that 
the functional capacity (that is, the quality) of HDL par-
ticles is more important from a prognostic point of view 
than circulating cholesterol concentrations (that is, the 
quantity), at least in T2DM patients. As a consequence, 
criteria and targets for lipid-lowering therapies might 
also be reconsidered.
Deaths from infectious diseases
We found a U-shaped association between HDL cho-
lesterol level and mortality with infectious causes, since 
both lower and higher HDL cholesterol concentrations 
were associated with an increased risk. Moreover, a sig-
nificant association was found between the higher HDL 
cholesterol tertile and mortality related to diabetes. 
Since the great majority of deaths as attributed to dia-
betes were associated with diabetic foot complications 
(data not shown), we can relate this latter finding to the 
infectious diseases group. Even if our results do not nec-
essarily imply causality and are difficult to completely 
understand, data supporting these associations exist in 
the literature [36–42]. Statistically significant U-shaped 
associations between HDL cholesterol levels and CRP 
serum concentrations have been reported, even if no 
data about the origin of inflammation are available [10]. 
Other clinical studies have found relationships between 
HDL cholesterol values and infections, either reporting 
associations between low HDL cholesterol at hospital 
admission and an increased risk of short-term infectious 
complications in relation to hospitalization, identifying a 
linear inverse correlation between HDL cholesterol and 
risk of infection or sepsis [36, 37] or reporting low HDL 
cholesterol as a risk factor for nosocomial infections [38, 
39]. To the best of our knowledge, only two population-
based cohort studies have evaluated the relationships 
between HDL cholesterol serum concentrations and the 
risk of community-acquired infectious diseases or sep-
sis. One study failed to identify an association between 
HDL cholesterol and the risk for long-term sepsis [40]. 
The second study, carried out with more than 100,000 
individuals, found a U-shaped relationship between HDL 
cholesterol levels and infectious diseases requiring hos-
pitalization and deaths due to infections; in particular 
bacterial infections (pneumonia, cutaneous and urinary 
infections) were associated with both lower and higher 
HDL cholesterol, and viral infections were associated 
only with lower HDL cholesterol values [41].
Both low (HDL cholesterol < 31 mg/dL) and high (HDL 
cholesterol > 100 mg/dL) concentrations of HDL choles-
terol significantly increased the risk for infectious dis-
ease-related admissions and mortality.
HDL particles are known to confer protection against 
bacterial and parasitic infections via several biochemi-
cal pathways. Preclinical studies have demonstrated 
that lipopolysaccharides from gram-negative bacteria 
and lipoteichoic acid from gram-positive bacteria are 
bound and cleared by HDL particles via ApoA-I [43–
45]. Therefore, the inability to remove bacterial toxins 
from the bloodstream might explain the increased risk 
for infectious diseases and related adverse events in 
individuals with low HDL cholesterol values. Moreo-
ver, HDL particles regulate innate and adaptive immu-
nity at different stages, from controlling hematopoiesis 
to modulating circulating leucocyte activity [46]. The 
acute phase reaction induced by infections promptly 
induces major structural and functional changes in 
HDL particles that lead to a loss of anti-inflammatory 
properties [3, 47–49]. Hence, dysfunctional HDL parti-
cles could fail to sustain the immune system to prevent 
the unfavorable consequences of sepsis.
On the other hand, very little is known about the 
mechanisms that might underlie the unfavorable effects 
of high HDL cholesterol levels on the risk of infec-
tious diseases. Very high HDL cholesterol levels could 
be due to genetic polymorphisms that are related 
both to higher HDL cholesterol concentrations and to 
increased disease susceptibility, although no direct cau-
sality can be inferred [50, 51]. During the process of 
infection, patients displaying high HDL cholesterol lev-
els might undergo an important displacement of con-
stitutive ApoA-I, the major anti-inflammatory element 
of HDL particles, mediated by the acute-phase pro-
teins serum amyloid A (SAA) and secretory phospho-
lipase A2 (sPLA2), in a way that could amplify systemic 
inflammation [52].
Limitations of the study
This study suffers from some limitations. Neither data 
about inflammatory status, which could be helpful in 
better understanding its relationship with the lipidic 
profile, nor data related to the specific infectious dis-
eases were available. Markers of HDL functionality, 
HDL subspecies and apolipoproteins, and cholesterol 
efflux capacity were not studied. Only baseline lipid 
values were collected. Indeed, misclassification of the 
patients could have reduced the association found.
The possibility of residual confounding factors could 
not be excluded owing to the observational nature of 
the study. The long follow-up period could have influ-
enced the results. Finally, comparing studies with 
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different cut-off values and reference ranges limits the 
interpretation of the existing literature.
The strengths of our study are the representativeness 
of our cohort of T2DM patients in the study area and 
the length and completeness of the follow-up.
Conclusion
We found a significant U-shaped association between HDL 
cholesterol and mortality associated with infectious dis-
eases in a population-based cohort of T2DM patients, but 
no statistically significant associations were found between 
HDL cholesterol and all-cause and CV and cancer mortal-
ity. These results, which need to be confirmed by further 
studies, corroborate the hypothesis that HDL cholesterol 
levels are nonprotective in T2DM patients.
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